NCT02650375 - Study of Metatinib Tromethamine Tablet | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

October 31, 2017

Study Completion Date

February 28, 2018

Conditions

Advanced or Metastatic Gastric CancerAdvanced or Metastatic Liver CancerAdvanced or Metastatic CRCAdvanced or Metastatic Non Squamous NSCLC

Interventions

DRUG

Metatinib Tromethamine

Patients receive Metatinib orally 200mg once daily (QD) or 100mg twice daily (BID) until disease progression or unacceptable toxicity occurred.

Trial Locations (3)

RECRUITING

The First Bethune Hospital of Jilin University, Changchun

RECRUITING

The First Affiliated Hospital, Zhejiang University, Hangzhou

RECRUITING

West China Hospital, Sichuan University, Chengdu